Royalty Pharma plc (RPRX) Reports Q2 Revenue of $555 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Royalty Pharma Reports Second Quarter 2021 Results
August 11, 2021 7:00 AM EDTStrong growth in net cash provided by operating activities (GAAP) and Adjusted Cash Flow(2)
Announced transactions of up to $2.8 billion in 2021, including $2.1 billion* in upfront paymentsIncreased 2021 guidance: Adjusted Cash Receipts(1) expected to be $2,080 to $2,120 million
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts(1) (a... More
